Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903147 | 0.79 | SRC (0.43) | GABRA1GABRG2GABRB3GABRA3KDR | |
| SCHEMBL4899157 | 0.77 | CCNE1 (0.35) | GABRA1GABRG2GABRB3GABRA3KDR | |
| SCHEMBL4891091 | 0.76 | SRC (0.34) | GABRA1GABRG2GABRB3GABRA3KDR | |
| SCHEMBL4903106 | 0.70 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL24958950 | 0.70 | TRPM5 (0.45) | KDRTRPM5 | |
| SCHEMBL30029030 | 0.70 | TRPM5 (0.45) | KDRTRPM5 | |
| SCHEMBL29539234 | 0.70 | CCR1 (0.46) | GABRA1GABRG2GABRB3GABRA3TGFBR1 | |
| SCHEMBL229994 | 0.70 | CCR1 (0.46) | GABRA1GABRG2GABRB3GABRA3TGFBR1 | |
| SCHEMBL4905135 | 0.68 | RAB9A (0.53) | — | |
| SCHEMBL700152 | 0.68 | CCR1 (0.46) | GABRA1GABRG2GABRB3GABRA3TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | ICAGEN, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| CN-1980923-A | Polycyclic pyridines as potassium ion channel modulators | ICAGEN INC (US) | 2007-06-13 | — | — | CN | disclosed |
| EP-1737852-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100349-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | KCNJ2, KCNH2, KCNQ1 | GABRA1 256/4885GABRG2 380/4885GABRB3 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.